enVVeno Medical Corp (NVNO) stock
Close on Nov 18, 2026Market cap $4.01MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $4.01M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.24
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$15.55M
- EPS, diluted
- -$23.56
- Free cash flow
- -$15.57M
- Book value per share
- $24.35
- Diluted shares
- 1M
Trading
- Previous close
- $5.77
- Open
- $5.77
- Day's range
- $5.53 – $6.30
- Volume
- 18,105
- Average volume (20 days)
- 27,593
- Beta (5 years)
- 1.21
- 52-week range
- $5.53 – $14.67
- RSI (14 days)
- 28.7
- Volatility (1 year)
- 79.8%
- Relative volume
- 0.67×
- WACC
- 11.1%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.
| Period | NVNO | S&P 500 | Difference | NVNO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -22.8% | -4.3% | −18.4 pts | ||
| 3 months | -47.7% | -4.6% | −43.1 pts | ||
| Year to date | -48.6% | +7.9% | −56.5 pts | ||
| 1 year | -50.0% | +11.8% | −61.8 pts | ||
| 3 years | -96.1% | +68.0% | −164.0 pts | -66.0% | +18.9% |
| 5 years | -97.7% | +66.2% | −163.9 pts | -53.0% | +10.7% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases enVVeno Medical filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Update
- Update
- Update
About enVVeno Medical
Surgical & Medical Instruments & Apparatus
enVVeno Medical Corporation is a medical device company developing tissue-based bioprosthetic solutions to treat venous disease, specifically targeting patients with severe chronic venous insufficiency of the deep venous system. The company develops replacement venous valves to restore unidirectional blood flow toward the heart and lungs, counteracting blood pooling and high venous pressure in the lower legs. Its primary product pipeline centers on the enVVe System, a transcatheter, non-surgical replacement valve that includes a delivery device, accessories, nose cone, and crimping mechanism. The device aims to serve patients suffering from severe chronic venous insufficiency and related leg ulcers, with implant procedures intended for vascular surgeons, interventional radiologists, and interventional cardiologists.
Company profile, executives and historyenVVeno Medical stock: common questions
What is enVVeno Medical's stock price?
NVNO closed at $5.77 on Nov 18, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $5.53 and $14.67.
What is enVVeno Medical's market cap?
enVVeno Medical was worth $4.01M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.
What is NVNO's P/E ratio?
enVVeno Medical lost money over the twelve months to Sep 30, 2026 (diluted EPS -$23.56), so it has no meaningful P/E ratio.
Does enVVeno Medical pay a dividend?
No. enVVeno Medical has not paid a cash dividend over the last twelve months.
How has NVNO stock performed over the past year?
Including dividends, NVNO returned -50.0% over the past year, against +11.8% for the S&P 500.
How many NVNO shares are sold short?
0M shares were sold short at the latest FINRA report, 3.87% of the float, or 1.0 days of average trading volume.
Who are enVVeno Medical's competitors?
Companies most similar to enVVeno Medical by business, industry and size include NSPR, PEN, LMAT, ADGM, EBRCZ.
See a number that looks wrong?